Objective Study carcinogenicity of inorganic lead, classified as ‘probably carcinogenic’ to humans by the International Agency for Research on Cancer (brain, lung, kidney and stomach).
Methods We conducted internal and external analyses for cancer incidence in two cohorts of 29 874 lead-exposed workers with past blood lead data (Finland, n=20 752, Great Britain=9122), with 6790 incident cancers. Exposure was maximum measured blood lead.
Results The combined cohort had a median maximum blood lead of 29 μg/dL, a mean first blood lead test of 1977, and was 87% male. Significant (p<0.05) positive trends, using the log of maximum blood lead, were found for brain cancer (malignant), Hodgkin’s lymphoma, lung cancer and rectal cancer, while a significant negative trend was found for melanoma. Borderline significant positive trends (0.05≤p≤0.10) were found for oesophageal cancer, meningioma and combined malignant/benign brain cancer. Categorical analyses reflected these trends. Significant interactions by country were found for lung, brain and oesophageal cancer, with Finland showing strong positive trends, and Great Britain showing modest or no trends. Larynx cancer in Finland also showed a positive trend (p=0.05). External analyses for high exposure workers (maximum blood lead >40 μg/dL) showed a significant excess for lung cancer in both countries combined, and significant excesses in Finland for brain and lung cancer. The Great Britain data were limited by small numbers for some cancers, and limited variation in exposure.
Conclusions We found strong positive incidence trends with increasing blood lead level, for several outcomes in internal analysis. Two of these, lung and brain cancer, were sites of a priori interest.
- occupational health practice
Statistics from Altmetric.com
Contributors KS and VB worked on all phases of the study, including data collection, analysis and writing. AA and MS participated by providing the cohort data from Finland, providing Finnish cancer rates and also participated in the writing. DMMcE, WM and PR participated by providing the cohort data from Great Britain, providing cancer rates from Great Britain and participated in the writing. KS participated in helping store the data at a common site, facilitating Dr Steenland’s stay at IARC and in writing the paper.
Funding This work was partly funded by a grant from the National Institute for Occupational Health and Safety (NIOSH), Grant 5R01OH010745-04.
Competing interests None declared.
Ethics approval This study was approved by the Emory Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Correction notice This article has been corrected since it published Online First.
Patient consent for publication Not required.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.